Tag: Featured

FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin)

January 21, 2019 todi0

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have […]

Smart microrobots that can adapt to their surroundings

January 18, 2019 todi0

One day we may be able to ingest tiny robots that deliver drugs directly to diseased tissue, thanks to research being carried out at EPFL and ETH Zurich. The group of scientists – led by Selman Sakar at EPFL and Bradley Nelson at ETH Zurich – drew inspiration from bacteria to design smart, biocompatible microrobots […]

Amgen and UCB receive positive vote from FDA Advisory Committee in favor of approval for EVENITY™ (romosozumab)

January 17, 2019 todi0

Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture after reviewing safety and efficacy data from the pivotal Phase […]

Nanoparticle breakthrough in the fight against cancer

January 17, 2019 todi0

A team of researchers, affiliated with UNIST has recently introduced a novel targeted drug delivery system that can improve the pharmacological and therapeutic properties of conventional cancer treatments. The new technology has dramatically enhanced safety and efficiency through the use of the supramolecularly built protein corona shield as a targeting agent through regulating the interfaces […]

Abbott to acquire Cephea Valve Technologies, Inc.

January 16, 2019 todi0

Abbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease. Financial terms were not disclosed. Abbott provided capital and secured an option to purchase Cephea in 2015. Cephea’s technology […]

Merck welcomes ten new startups to its Innovation Center

January 16, 2019 todi0

Merck, a leading science and technology company, today announced the ten startups that will be joining the seventh intake of its Accelerator program at the Merck Innovation Center in Darmstadt. The teams come from nine different countries, making 2019 the most international intake in the Merck Accelerator’s history. They were chosen from a total of […]

Sleeping less than six hours a night may increase cardiovascular risk

January 16, 2019 todi0

People who sleep less than six hours a night may be at increased risk of cardiovascular disease compared with those who sleep between seven and eight hours, suggests a new study published in the Journal of the American College of Cardiology. Poor quality sleep increases the risk of atherosclerosis – plaque buildup in the arteries […]

European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma

January 15, 2019 todi0

Bristol-Myers Squibb Company (NYSE: BMY) announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (“low-dose”) for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).

Muscle stem cells can drive cancer that arises in Duchenne muscular dystrophy

January 15, 2019 todi0

People with Duchenne muscular dystrophy (DMD) can develop an otherwise-rare muscle cancer, called rhabdomyosarcoma, due to the muscle cells’ continuous work to rebuild the damaged tissue. However, little is known about how the cancer arises, hindering development of a treatment or test that could predict cancer risk. Now, scientists from Sanford Burnham Prebys Medical Discovery […]

SMi presents the 2nd Annual Conference: Injectable Drug Delivery 2019

January 14, 2019 todi0

15 – 16 May 2019, London, UK. The global injectable drug delivery market is expected to grow from $400 billion to $1200 billion by 2046 with a CAGR of 12.8%. Injectable drug delivery is a method of drug administration into the body with a needle via various routes including intramuscular and intravenous.